1. Nagoshi T, Yoshimura M, Rosano GM et al. Optimization of cardiac metabolism in heart failure. Curr Pharm Des. 2011;17(35):3846–53. doi: 10.2174/138161211798357773 2. Rosano GM, Fini M, Caminiti G, Barbaro G. Cardiac metabolism in myocardial ischemia. Curr Pharm Des. 2008;14:2551–62. DOI: 10.2174/138161208786071317 3. Walter J. Paulus MD, PhD Elisa Dal Canto MD. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. ACC: Heart Failure. Volume 6, Issue 1, January 2018, Pages 1-7. doi: 10.1016/j.jchf.2017.07.012. 4. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease withrestrictive and dilated phenotypes. Eur Heart J 2015;36:1718–1727, 1718–1727c doi: 10.1093/eurheartj/ehv134. 6. Dinesh Shah A, Langenberg C, Rapsomaniki E et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet 2015 Feb;3(2):105-13. DOI: 10.1016/S2213-8587(14)70219-0 7. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014 Sep;1(1):4-25. DOI: 10.1002/ehf2.12005